Do patients with chronic kidney disease usually have lower hemoglobin and hematocrit?

Do Patients with CKD Usually Have Lower Hemoglobin and Hematocrit?

Yes, patients with chronic kidney disease typically develop progressively lower hemoglobin and hematocrit levels as kidney function declines, with anemia becoming consistently present when GFR falls below 60 mL/min/1.73 m² (CKD stage 3 and beyond). 1

Relationship Between Kidney Function and Hemoglobin Levels

The decline in hemoglobin and hematocrit is directly related to the severity of kidney dysfunction:

• Mean hemoglobin levels decrease consistently only when GFR drops below 60 mL/min/1.73 m² (stage 3 CKD), though some variability exists at any given level of kidney function 1
• The steepest decline occurs at lower GFR levels: For patients with baseline eGFR of 20 mL/min/1.73 m², hematocrit drops by 3.7% for every 10 mL/min/1.73 m² decline in GFR, compared to only 0.5% decline for those with baseline eGFR of 60 mL/min/1.73 m² 2
• Both men and women show progressively lower hematocrit when eGFR falls below 50 mL/min/1.73 m², with statistically significant differences from normal kidney function 1

Prevalence of Anemia by CKD Stage

The prevalence of anemia increases dramatically as CKD progresses:

• CKD Stage 2 (GFR 60-89): Relatively low prevalence in general population, but 8.7% in high-risk patients with diabetes 1
• CKD Stage 3 (GFR 30-59): 7.5% prevalence in diabetic patients, 5.0% in non-diabetic patients 1
• CKD Stage 4 (GFR 15-29): 22.2% prevalence in diabetic patients, 7.9% in non-diabetic patients 1
• CKD Stage 5 (GFR <15): 52.4% prevalence in diabetic patients, 50% in non-diabetic patients 1

Diagnostic Thresholds for Anemia in CKD

Anemia should be diagnosed and evaluated at these hemoglobin levels:

• Men: Hemoglobin <13.5 g/dL 1, 3
• Women: Hemoglobin <12.0 g/dL 1, 3

These thresholds are lower than normal population ranges, reflecting the expected decline in CKD patients 1.

Factors That Accelerate Hemoglobin Decline

Certain patient characteristics are associated with more pronounced drops in hemoglobin:

• Male sex: Men experience greater hematocrit declines per unit decrease in eGFR compared to women 2
• Younger age (<65 years): Associated with steeper hemoglobin decline as kidney function worsens 2
• Baseline proteinuria (protein-to-creatinine ratio >0.22): Predicts more rapid hematocrit decline 2
• Diabetes: Anemia is more prevalent, more severe, and occurs earlier in diabetic CKD patients compared to non-diabetic patients 1

Clinical Implications

All CKD patients should have hemoglobin measured at least annually, regardless of CKD stage or cause, because anemia can develop at any stage and is associated with increased mortality and cardiovascular complications 1. More frequent monitoring (every 3 months) is warranted for patients with GFR <30 mL/min/1.73 m², greater disease burden, unstable clinical course, or documented previous hemoglobin decline 4.

Important Caveats

Significant variability exists in hemoglobin levels at any given level of kidney function 1. Not all CKD patients will be anemic, particularly in earlier stages (stages 1-2), and the presence of anemia does not automatically mean it is caused by CKD—other contributing factors such as iron deficiency, blood loss, or bone marrow disorders must be evaluated 1, 5.

The lowest hemoglobin levels are found in anephric patients and those who commence dialysis at very low levels of kidney function 1. Hemodialysis patients typically have hemoglobin values around 8.9-10.2 g/dL and hematocrit around 24.8-27.2% without erythropoiesis-stimulating agent therapy 6.